CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 275 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04318301
NCT04318301N/ACompleted

Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study

Zhenhua Zen·observational·Posted Mar 23, 2020·Updated Apr 29, 2020

In Brief

An observational study for COVID-19 and Hypertension. Completed, enrolled 275 participants across 1 site.

Detailed Summary

Some studies have shown that the main pathogenesis of patients with covid19 is related to ACE2 receptor. Lung is one of the main organs, and there are many ACE2 receptors in cardiovascular system. ACEI / ARB is the main target of antihypertensive drugs. Previous reports suggested that there were large number of patients with covid19 also suffered from hypertension, suggesting that patients with hypertension may be the susceptible to covid19. Therefore, we try to follow up the patients admitted to Hankou hospital to explore the impact of hypertension and hypertension treatment on the severity and prognosis of patients with covid19, so as to provide new methods for the treatment of patients with covid19 in the future.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMar 23, 2020
Enrollment StartMar 21, 2020
Primary CompletionMar 28, 2020
Study CompletionMar 30, 2020
TodayJul 2, 2026
Enrollment to primary: 7 daysPosted 6.3 years ago